On August 31, 2022 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported that it will present a company update at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference) (Press release, Anixa Biosciences, AUG 31, 2022, https://ir.anixa.com/news/detail/1000/anixa-biosciences-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference [SID1234618830]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will provide an overview of Anixa’s business and highlight recent corporate achievements, including the treatment of the first patient in Anixa’s CAR-T based ovarian cancer clinical trial.

A replay of the presentation will be available for 90 days at the link above or by visiting the Investors section of Anixa’s website at View Source

Anixa management will also be available for one-on-one meetings throughout the conference. Please contact your representative at H.C. Wainwright to request a meeting.